Core Viewpoint - A class action lawsuit has been filed against LifeMD, Inc. for allegedly misleading investors about its business prospects and competitive position during a specified period in 2025 [1][2]. Allegations - The complaint alleges that LifeMD's management materially overstated the company's competitive position and recklessly raised its 2025 guidance without properly accounting for rising customer acquisition costs in its RexMD segment and related to obesity treatment drugs [2]. - The statements made by the defendants regarding LifeMD's business operations and prospects were claimed to be materially false and misleading [2]. Financial Impact - Following the announcement of its second quarter 2025 results, which included a revision of full-year guidance due to "temporary challenges" in the RexMD business, LifeMD's stock price dropped by $5.31, or 44.8%, closing at $6.53 on August 6, 2025 [3]. Class Action Participation - Shareholders interested in participating as lead plaintiffs in the class action must file their papers by October 27, 2025, although they can remain absent class members without taking action [4].

Group 1 - A class action has been filed on behalf of investors who purchased Replimune Group, Inc. (NASDAQ: REPL) securities between November 22, 2024, and July 21, 2025 [1] - Robbins LLP is investigating allegations that Replimune Group, Inc. misled investors regarding the viability of its IGNYTE trial, claiming that the company overstated the trial's prospects and failed to disclose material issues [2] - On July 22, 2025, Replimune announced it received a complete response letter (CRL) from the FDA, indicating that the IGNYTE trial was not considered adequate, leading to a significant stock price drop of $9.52 per share, or 77.24%, closing at $2.80 per share [3] Group 2 - Shareholders interested in participating as lead plaintiffs must file their papers with the court by September 22, 2025, and can remain absent class members if they choose not to participate [4] - Robbins LLP operates on a contingency fee basis, meaning shareholders pay no fees or expenses [5] - The firm has been dedicated to helping shareholders recover losses and improve corporate governance since 2002 [5]

Core Viewpoint - A class action has been filed against Capricor Therapeutics, Inc. for allegedly misleading investors regarding the viability of its lead product candidate, deramiocel, for treating Duchenne muscular dystrophy (DMD) [1][2]. Group 1: Company Overview - Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing cell and exosome-based therapeutics for DMD and other diseases with unmet medical needs in the U.S. [1] - The company's lead product candidate is deramiocel, which consists of allogeneic cardiosphere-derived cells [1]. Group 2: Allegations and Legal Action - Robbins LLP is investigating allegations that Capricor misled investors about deramiocel's potential for first approval for DMD cardiomyopathy while concealing adverse safety and efficacy data from its Phase 2 HOPE-2 trial [2]. - The complaint states that the misleading information led to shareholders purchasing Capricor's securities at artificially inflated prices [2]. Group 3: Stock Price Impact - On July 11, 2025, Capricor announced it received a Complete Response Letter (CRL) from the FDA, denying its Biologics License Application due to insufficient evidence of effectiveness and the need for additional clinical data [3]. - Following the announcement, Capricor's stock price fell from $11.40 per share on July 10, 2025, to $7.64 per share on July 11, 2025 [3].

Group 1 - The core issue involves a class action lawsuit against Spectrum Pharmaceuticals, alleging false or misleading statements regarding its Pinnacle Study related to the drug poziotinib for lung cancer treatment [2] - The Lead Plaintiff appointment process for the class action has reopened, allowing shareholders who purchased shares between March 17, 2022, and September 22, 2022, to file their papers by September 24, 2025 [1][3] - Spectrum Pharmaceuticals focuses on acquiring, developing, and commercializing novel and targeted oncology therapies [1] Group 2 - The lawsuit claims that the company misrepresented information that could affect investor decisions, particularly concerning the clinical trial results of poziotinib [2] - Robbins LLP, the law firm involved, emphasizes that shareholders do not need to participate in the case to be eligible for recovery [3] - The firm operates on a contingency fee basis, meaning shareholders incur no fees or expenses unless there is a recovery [4]

Core Viewpoint - A class action lawsuit has been filed against PubMatic, Inc. for allegedly misleading investors about its business prospects during a specific period, leading to a significant drop in stock price following the release of disappointing financial results [1][2][3]. Company Overview - PubMatic, Inc. is a technology company that facilitates real-time programmatic advertising transactions for advertisers, agencies, and demand-side platforms (DSPs) [1]. Allegations - The lawsuit claims that during the class period, PubMatic failed to disclose critical information regarding a major DSP buyer shifting clients to a new platform, which impacted ad spend and revenue [2]. - The complaint highlights that on August 11, 2025, PubMatic reported a reduction in ad spend from one of its top DSP partners, which was attributed to the shift in inventory evaluation methods by the DSP [3]. Financial Impact - Following the announcement of the second quarter 2025 financial results, PubMatic's stock price fell by $2.23, or 21.1%, closing at $8.34 per share on August 12, 2025 [3]. Legal Proceedings - Shareholders interested in participating in the class action must submit their papers by October 20, 2025, to serve as lead plaintiff, representing the interests of other class members [4].

Core Viewpoint - A class action lawsuit has been filed against Snap Inc. for allegedly misleading investors about its business prospects, particularly regarding advertising revenue and growth expectations during the specified period [1][2]. Allegations - The complaint claims that Snap's management created a false impression of having reliable information about expected advertising revenue while downplaying macroeconomic instability [2]. - Snap's optimistic reports on advertising growth were found to be misleading, as they were overly reliant on the company's execution capabilities, which were already faltering [2]. Financial Results and Stock Impact - On August 5, 2025, Snap reported a slowdown in advertising revenue growth, attributing it to issues with its ad platform and external factors like the timing of Ramadan [3]. - Following this announcement, Snap's stock price dropped from $9.39 per share to $7.78 per share, marking a decline of over 17% [3]. Class Action Participation - Shareholders may be eligible to participate in the class action against Snap Inc. and can contact Robbins LLP for more information [3]. - Individuals interested in serving as lead plaintiffs are encouraged to reach out, although participation is not required for recovery eligibility [3]. About Robbins LLP - Robbins LLP is a recognized leader in shareholder rights litigation, focusing on helping shareholders recover losses and improve corporate governance since 2002 [4].

Group 1 - A class action has been filed against Snap Inc. on behalf of investors who acquired its securities between April 29, 2025, and August 5, 2025 [1] - The allegations state that Snap misled investors about its advertising revenue and growth prospects, creating a false impression of reliable information while downplaying macroeconomic instability [2] - On August 5, 2025, Snap reported a slowdown in advertising revenue growth, attributing it to issues with its ad platform and other factors, leading to a stock price decline of over 17% from $9.39 to $7.78 per share [3] Group 2 - Robbins LLP is investigating the claims and encourages shareholders to participate in the class action, with options to serve as lead plaintiff or remain an absent class member [3] - The representation in the class action is on a contingency fee basis, meaning shareholders will not incur fees or expenses [4]

Core Viewpoint - A class action lawsuit has been filed against PubMatic, Inc. for allegedly misleading investors about its business prospects during a specific period, leading to a significant drop in stock price following the release of disappointing financial results [1][2][3]. Company Overview - PubMatic, Inc. is a technology company that facilitates real-time programmatic advertising transactions for advertisers, agencies, and demand-side platforms (DSPs) [1]. Allegations - The lawsuit claims that during the class period, PubMatic failed to disclose critical information regarding a top DSP buyer shifting clients to a new platform, which affected ad spend and revenue [2]. - The complaint highlights that on August 11, 2025, PubMatic reported a reduction in ad spend from one of its top DSP partners, which was attributed to the shift in client evaluation methods [3]. Financial Impact - Following the announcement of the second quarter 2025 financial results, PubMatic's stock price fell by $2.23, or 21.1%, closing at $8.34 per share on August 12, 2025 [3]. Legal Proceedings - Shareholders interested in participating in the class action must submit their papers by October 20, 2025, to serve as lead plaintiff [4]. - The lead plaintiff will represent other class members in directing the litigation, but participation is not required for recovery [4]. Firm Background - Robbins LLP is noted for its focus on shareholder rights litigation, aiming to help shareholders recover losses and improve corporate governance since 2002 [5].

Core Viewpoint - The Schall Law Firm is investigating potential breaches of fiduciary duty by the directors and management of Olo Inc. in relation to its acquisition by Thoma Bravo for $10.25 per share [1]. Group 1 - The investigation by the Schall Law Firm focuses on whether the Olo board acted in the best interests of its shareholders during the acquisition process [1]. - Olo Inc. has agreed to be acquired by Thoma Bravo at a price of $10.25 per share [1].

Core Viewpoint - A class action has been filed against Biohaven Ltd. for allegedly misleading investors regarding the viability of its drug candidates, particularly troriluzole and BHV-7000, during the period from March 24, 2023, to May 14, 2025 [1][2]. Group 1: Company Overview - Biohaven Ltd. is a biopharmaceutical company focused on developing therapies in immunology, neuroscience, and oncology [1]. - The company is working on several product candidates, including troriluzole for spinocerebellar ataxia (SCA) and BHV-7000 for bipolar disorder [1]. Group 2: Allegations and Legal Action - The class action alleges that Biohaven overstated the regulatory prospects and data sufficiency for troriluzole's approval for SCA [2]. - It is also claimed that the efficacy and clinical prospects of BHV-7000 for bipolar disorder were similarly overstated [2]. - The complaint suggests that the eventual revelation of these issues could significantly negatively impact Biohaven's business and financial condition [2]. Group 3: Class Action Participation - Shareholders interested in serving as lead plaintiffs must file their papers by September 12, 2025 [3]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [3].